These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Evaluation of end-tidal CO Higashi A; Dohi Y; Yamabe S; Kinoshita H; Sada Y; Kitagawa T; Hidaka T; Kurisu S; Yamamoto H; Yasunobu Y; Kihara Y Heart Vessels; 2017 Nov; 32(11):1350-1357. PubMed ID: 28560485 [TBL] [Abstract][Full Text] [Related]
5. Mixed-expired and end-tidal CO2 distinguish between ventilation and perfusion defects during exercise testing in patients with lung and heart diseases. Hansen JE; Ulubay G; Chow BF; Sun XG; Wasserman K Chest; 2007 Sep; 132(3):977-83. PubMed ID: 17573506 [TBL] [Abstract][Full Text] [Related]
6. Cardiopulmonary exercise testing to detect chronic thromboembolic pulmonary hypertension in patients with normal echocardiography. Held M; Grün M; Holl R; Hübner G; Kaiser R; Karl S; Kolb M; Schäfers HJ; Wilkens H; Jany B Respiration; 2014; 87(5):379-87. PubMed ID: 24732343 [TBL] [Abstract][Full Text] [Related]
7. Pulmonary hypertension in interstitial lung disease: prevalence, prognosis and 6 min walk test. Andersen CU; Mellemkjær S; Hilberg O; Nielsen-Kudsk JE; Simonsen U; Bendstrup E Respir Med; 2012 Jun; 106(6):875-82. PubMed ID: 22425136 [TBL] [Abstract][Full Text] [Related]
9. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. Garin MC; Highland KB; Silver RM; Strange C J Rheumatol; 2009 Feb; 36(2):330-6. PubMed ID: 19208563 [TBL] [Abstract][Full Text] [Related]
10. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. Launay D; Mouthon L; Hachulla E; Pagnoux C; de Groote P; Remy-Jardin M; Matran R; Lambert M; Queyrel V; Morell-Dubois S; Guillevin L; Hatron PY J Rheumatol; 2007 May; 34(5):1005-11. PubMed ID: 17444586 [TBL] [Abstract][Full Text] [Related]
11. [Peak oxygen uptake during the six-minute walk test in diffuse interstitial lung disease and pulmonary hypertension]. Blanco I; Villaquirán C; Valera JL; Molina-Molina M; Xaubet A; Rodríguez-Roisin R; Barberà JA; Roca J Arch Bronconeumol; 2010 Mar; 46(3):122-8. PubMed ID: 20138698 [TBL] [Abstract][Full Text] [Related]
12. Cardiopulmonary exercise test characteristics in patients with chronic obstructive pulmonary disease and associated pulmonary hypertension. Holverda S; Bogaard HJ; Groepenhoff H; Postmus PE; Boonstra A; Vonk-Noordegraaf A Respiration; 2008; 76(2):160-7. PubMed ID: 17960052 [TBL] [Abstract][Full Text] [Related]
13. End-tidal PCO2 abnormality and exercise limitation in patients with primary pulmonary hypertension. Yasunobu Y; Oudiz RJ; Sun XG; Hansen JE; Wasserman K Chest; 2005 May; 127(5):1637-46. PubMed ID: 15888840 [TBL] [Abstract][Full Text] [Related]
14. Pulmonary hypertension in chronic obstructive and interstitial lung diseases. Andersen CU; Mellemkjær S; Nielsen-Kudsk JE; Bendstrup E; Hilberg O; Simonsen U Int J Cardiol; 2013 Oct; 168(3):1795-804. PubMed ID: 23849967 [TBL] [Abstract][Full Text] [Related]
15. Comparison of change in end tidal carbon dioxide after three minutes of step exercise between systemic sclerosis patients with and without pulmonary hypertension. Bernstein EJ; Gordon JK; Spiera RF; Huang WT; Horn EM; Mandl LA Rheumatology (Oxford); 2017 Jan; 56(1):87-94. PubMed ID: 28028158 [TBL] [Abstract][Full Text] [Related]